Trial reportFuture oncology (London, England)2025
Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.
Trial report in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02737501 (A Phase 3 Multicenter Open-label Study of Brigatinib), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis retrospective, chart-review study evaluated real-world outcomes post-frontline brigatinib in ALTA-1L.
methodsPatients from ALTA-1L were followed after brigatinib discontinuation. Outcomes evaluated for second-line (2L) treatment included real-world overall response rate (rwORR), time to treatment discontinuation (rwTTD), and progression-free survival (rwPFS).
resultsForty of 48 patients received subsequent systemic anticancer therapies; 30 received 2L ALK tyrosine kinase inhibitors (TKIs), mostly lorlatinib (n = 16) or alectinib (n = 8), and 11 received 2L non-ALK TKI therapy (one with alectinib). rwORR was 33% with 2L ALK TKIs and 0% with 2L non-ALK TKI therapy. Median (95% confidence interval [CI]) 2L rwTTD was 34.7 months (4.6-not reached [NR]) for ALK TKIs (lorlatinib, 37.2 months [6.0-NR]; alectinib, NR [1.1-NR]; crizotinib, 2.8 months [2.0-NR]) and 4.4 months (1.4-6.0) for 2L non-ALK TKI therapy. Median (95% CI) 2L rwPFS was 16.1 months (4.4-NR) with ALK TKIs (lorlatinib, 25.6 months [3.8-NR]; alectinib, 16.1 months [1.1-NR]; crizotinib, 2.4 months [2.0-NR]) and 6.1 months (1.7-NR) with 2L non-ALK TKI therapy.
conclusionsFollowing brigatinib discontinuation, most patients initiated a second ALK TKI. Patients treated with 2L second- or third-generation ALK TKIs post-brigatinib experienced prolonged clinical benefit. CLINICAL
trial registrationclinicaltrials.gov identifier: NCT02737501.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.